Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome

Inclusion Criteria:

• Age: 18-75 years old
• Some clear risk aetiological agents of acute respiratory distress syndrome
• Acute onset, with corresponding clinical manifestations
• PaO2/FiO2 ≤ 300mmHg
• Chest radiograph or chest computerized tomography prompting bilateral pulmonary infiltrate shadow
• pulmonary capillary wedge pressure (PCWP) ≤ 18 mmHg or clinical cardiogenic pulmonary edema can be excluded
• respiratory rate (RR) ≥ 30bpm and (or) respiratory distress
• requiring tracheal intubation or tracheostomy for invasive mechanical ventilation
• or have received invasive mechanical ventilation time ≤ 3 days

Exclusion Criteria:

• Age: < 18 years old or > 75 years old
• During the early stage of the treatment, the use of mechanical ventilation for more than 3 days other than ALI/ARDS for reasons
• Lung parenchyma and airway surgery carried out within 30 days of the screening period
• Severe arrhythmia and myocardial ischemia after cardiopulmonary resuscitation
• Systolic blood pressure < 90 mm Hg, and can not maintain its stability with intravenous infusion and vasopressor drugs
• Intubation due to interstitial lung disease (E.g., sarcoidosis, idiopathic pulmonary fibrosis)
• Any active pneumothorax or mediastinal emphysema
• Risk factors leading to the death within 3 months in addition to ALI/ARDS during the screening period (E.g., end-stage cancer)
• Of perfluorocarbons' allergies
• Pregnant, breastfeeding women
• Attending other clinical trial within 30 days of the screening period
• Severe organ dysfunction (Marshall score ≥ 3 or Sequential Organ Failure Assessment（SOFA） score≥ 3, including serious liver and kidney dysfunction, upper gastrointestinal hemorrhage, etc.)
• Acute Physiology and Chronic Health Evaluation（APACHE） II score ≥ 30, high risk of death
• The researchers consider other situations not suitable for the case to participate in the study